Synaptogenix's participation in the USC-sponsored forum as a speaker, alongside notable academics and a Nobel Laureate, is likely to boost the company's visibility and credibility in the field of neurodegenerative diseases. The presentation of statistically significant results for their lead therapeutic in severe Alzheimer's disease patients could positively influence investor perception and potentially increase stock demand in the short term.